Diasorin
ISIN: IT0003492391 | Ticker: DIA | LEI: 8156002878BDF0EE4348
Country: Italy
World leaders in the lab diagnostics market, we are specialists in the immunodiagnostics and molecular diagnostics segments and active in the Licensed Technology sector
The Company has been developing, producing and marketing reagent kits for laboratory diagnostics all over the world, for over 50 years. Our broad offering of diagnostic tests and Licensed Technology solutions, made available thanks to ongoing investments in research, positions us as the player with the widest range of specialty solutions in the sector and identifies the Group as the "Diagnostics Specialist".
Diagnosis is the first step towards understanding a person’s state of health. This is why our tests can make the difference: they are precise and reliable and enable delivery of early diagnosis of various pathologies for millions of people who will then be able to receive the most appropriate therapy.
2000
Served areaWorldwide
Headcount3,350
HeadquartersVia Crescentino snc, 13040 Saluggia – Italy
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | N/A | 26,000.00 | 26,000.00 | 26,000.00 |
| Other Noncurrent Assets | N/A | 2,189,000.00 | 4,323,000.00 | 3,722,000.00 |
| Current Trade Receivables | N/A | 165,678,000.00 | 217,588,000.00 | 220,035,000.00 |
| Cash and cash equivalents | 157,552,000.00 | 339,881,000.00 | 403,020,000.00 | 241,776,000.00 |
| Other Current Assets | N/A | 16,998,000.00 | 39,634,000.00 | 89,184,000.00 |
| Statutory Reserve | N/A | 11,190,000.00 | 11,190,000.00 | 11,190,000.00 |
| Other Noncurrent Liabilities | N/A | 48,155,000.00 | 43,983,000.00 | 17,287,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 65,485,000.00 | 84,773,000.00 | 104,204,000.00 |
| Other Current Payables | N/A | 60,688,000.00 | 102,319,000.00 | 103,304,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Profit (loss) | 248,296,000.00 | 310,732,000.00 | 240,110,000.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | 248,296,000.00 | 310,732,000.00 | 240,110,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 182,329,000.00 | 63,139,000.00 | -161,244,000.00 |
| Cash and cash equivalents | 157,552,000.00 | 339,881,000.00 | 403,020,000.00 | 241,776,000.00 |
Please note that some sums might not add up.
IT0003492391
LEI8156002878BDF0EE4348
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryFTSE MIB
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.